d-Lactate and intestinal fatty acid-binding protein are elevated in serum in patients with acute ischemic stroke

• Published in: Acta neurologica Belgica Vol. 121; no. 1; pp. 87 - 93
• Main Authors: Camara-Lemarroy, Carlos R., Escobedo-Zúñiga, Nicolás, Guzmán-de la Garza, Francisco J., Castro-Garza, Jorge, Vargas-Villarreal, Javier, Góngora-Rivera, Fernando
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.02.2021
• Subjects: Biomedical and Life Sciences; Biomedicine; Medicine/Public Health; Neurology; Neuroradiology; Neurosciences; Original Article; Intestinal barrier; Stroke; Biomarker; Ischemic stroke
• ISSN: 0300-9009; 2240-2993
• DOI: 10.1007/s13760-018-0940-x

Experimental studies suggest that the intestinal barrier is affected in ischemic stroke. d -Lactate and intestinal fatty acid-binding protein (IFABP) are markers of intestinal mucosa integrity and barrier function. Our purpose was to evaluate the serum concentrations of these markers in patients with acute ischemic stroke (AIS). We included patients with AIS and used healthy subjects as controls. Clinical, demographic and outcome measures were recorded. Blood was drawn within 24 h of symptom onset. Serum concentrations of d -Lactate and IFABP were determined using commercially available colorimetric and ELISA kits, respectively. We included a total of 61 patients (median age of 64 years). The majority of patients were male (57.4%). The most common cause of stroke was atherosclerosis (34.4%), followed by small-vessel disease and cardioembolic (32.7% each). Mean admission NIHSS score was 8. Median IFABP and d -Lactate concentrations were significantly higher in patients than in controls. Concentrations were not associated with stroke severity or 3-month outcome. Patients with large-artery atherosclerosis and cardioembolic etiology had higher d -Lactate values than patients with small-vessel disease. d -Lactate and IFABP were significantly elevated in patients with AIS. This suggests that there is disruption of the intestinal barrier in patients with AIS.